CY1110689T1 - Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια - Google Patents
Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδιαInfo
- Publication number
- CY1110689T1 CY1110689T1 CY20101100465T CY101100465T CY1110689T1 CY 1110689 T1 CY1110689 T1 CY 1110689T1 CY 20101100465 T CY20101100465 T CY 20101100465T CY 101100465 T CY101100465 T CY 101100465T CY 1110689 T1 CY1110689 T1 CY 1110689T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptide
- binding sites
- compositions
- antigen binding
- polyptopes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 230000027455 binding Effects 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 239000000178 monomer Substances 0.000 abstract 2
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP04803302A EP1691833B1 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110689T1 true CY1110689T1 (el) | 2015-06-10 |
Family
ID=34626385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100465T CY1110689T1 (el) | 2003-11-28 | 2010-05-27 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
| CY2016010C CY2016010I2 (el) | 2003-11-28 | 2016-05-05 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2016010C CY2016010I2 (el) | 2003-11-28 | 2016-05-05 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (OSRAM) |
| EP (2) | EP1691833B1 (OSRAM) |
| AT (1) | ATE459374T1 (OSRAM) |
| AU (1) | AU2004293182B2 (OSRAM) |
| BE (1) | BE2016C023I2 (OSRAM) |
| CA (1) | CA2544532C (OSRAM) |
| CY (2) | CY1110689T1 (OSRAM) |
| DE (1) | DE602004025840D1 (OSRAM) |
| DK (1) | DK1691833T3 (OSRAM) |
| ES (1) | ES2341252T3 (OSRAM) |
| FR (1) | FR16C1000I2 (OSRAM) |
| HU (1) | HUS1600019I1 (OSRAM) |
| LU (1) | LU93067I2 (OSRAM) |
| NL (1) | NL300807I2 (OSRAM) |
| PL (1) | PL1691833T3 (OSRAM) |
| PT (1) | PT1691833E (OSRAM) |
| SI (1) | SI1691833T1 (OSRAM) |
| WO (1) | WO2005052004A2 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2383297E (pt) | 2006-08-14 | 2013-04-15 | Xencor Inc | Anticorpos otimizados que visam cd |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| SMT201800319T1 (it) | 2010-10-27 | 2018-07-17 | Amgen Res Munich Gmbh | Mezzi e metodi per il trattamento del dlbcl |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| CN103687872A (zh) | 2011-04-22 | 2014-03-26 | 新兴产品开发西雅图有限公司 | 前列腺特异性膜抗原结合蛋白和相关组合物以及方法 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| DK3083686T4 (da) | 2013-12-17 | 2023-05-30 | Hoffmann La Roche | Fremgangsmåder til behandling af cancere ved anvendelse af PD-1-aksebindende antagonister og taxaner |
| JP2017501157A (ja) | 2013-12-17 | 2017-01-12 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法 |
| CN113549153A (zh) | 2014-05-29 | 2021-10-26 | 宏观基因有限公司 | 三特异性结合分子和其使用方法 |
| CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| AU2015342964B2 (en) | 2014-11-05 | 2021-06-24 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| MX388405B (es) | 2015-05-29 | 2025-03-19 | Genentech Inc | Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1. |
| EP3310815A1 (en) | 2015-06-17 | 2018-04-25 | F. Hoffmann-La Roche AG | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| DK3377103T4 (en) | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| CN110603266A (zh) | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| JP2019530434A (ja) | 2016-08-05 | 2019-10-24 | ジェネンテック， インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
| EP3497129A1 (en) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| CA3039430A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| PL3559034T3 (pl) | 2016-12-20 | 2021-04-19 | F. Hoffmann-La Roche Ag | Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137) |
| WO2019086497A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
| JP7159332B2 (ja) | 2018-03-13 | 2022-10-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ４－１ｂｂアゴニストと抗ｃｄ２０抗体の治療的組み合わせ |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| CN113195544A (zh) * | 2018-06-07 | 2021-07-30 | 库利南肿瘤股份有限公司 | 多特异性结合蛋白及其使用方法 |
| MX2021003213A (es) | 2018-09-21 | 2021-05-12 | Genentech Inc | Metodos de diagnostico para cancer de mama triple negativo. |
| AU2019375413A1 (en) | 2018-11-05 | 2021-05-27 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| CA3161283A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023531406A (ja) | 2020-06-16 | 2023-07-24 | ジェネンテック， インコーポレイテッド | トリプルネガティブ乳がんを処置するための方法および組成物 |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| WO2022169825A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| TW202346365A (zh) | 2022-03-23 | 2023-12-01 | 瑞士商赫孚孟拉羅股份公司 | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療 |
| AU2023251832A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| CN120152989A (zh) | 2022-11-03 | 2025-06-13 | 豪夫迈·罗氏有限公司 | 抗cd19/抗cd28双特异性抗体的组合疗法 |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| US20250115680A1 (en) | 2023-09-26 | 2025-04-10 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| ATE241011T1 (de) | 1991-02-27 | 2003-06-15 | Micromet Ag | Serin-reiche peptidlinker |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| ID27512A (id) * | 1998-04-21 | 2001-04-12 | Microment Ges Fur Biomedizinis | Polipeptid tetapan cd19xcd3 dan kegunaan-kegunaannya |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| AU2002363339B2 (en) * | 2001-11-08 | 2008-02-07 | Abbvie Biotechnology Ltd | Stable liquid pharmaceutical formulation of IGG antibodies |
-
2004
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en not_active Ceased
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I2/el unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK1691833T3 (da) | 2010-05-03 |
| NL300807I2 (OSRAM) | 2016-10-13 |
| EP2186527A1 (en) | 2010-05-19 |
| ATE459374T1 (de) | 2010-03-15 |
| WO2005052004A2 (en) | 2005-06-09 |
| US10000574B2 (en) | 2018-06-19 |
| FR16C1000I1 (OSRAM) | 2016-06-24 |
| WO2005052004A3 (en) | 2006-03-09 |
| PT1691833E (pt) | 2010-06-08 |
| CA2544532A1 (en) | 2005-06-09 |
| BE2016C023I2 (OSRAM) | 2023-12-18 |
| CY2016010I1 (el) | 2016-08-31 |
| EP1691833A2 (en) | 2006-08-23 |
| HUS1600019I1 (hu) | 2016-06-28 |
| ES2341252T3 (es) | 2010-06-17 |
| AU2004293182B2 (en) | 2010-02-18 |
| SI1691833T1 (sl) | 2010-06-30 |
| DE602004025840D1 (de) | 2010-04-15 |
| EP1691833B1 (en) | 2010-03-03 |
| AU2004293182A1 (en) | 2005-06-09 |
| LU93067I2 (fr) | 2016-07-11 |
| PL1691833T3 (pl) | 2010-08-31 |
| CA2544532C (en) | 2015-06-16 |
| CY2016010I2 (el) | 2016-08-31 |
| US20070249529A1 (en) | 2007-10-25 |
| FR16C1000I2 (fr) | 2017-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110689T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
| ATE370967T1 (de) | Polyspezifische bindemoleküle und deren verwendung | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| ATE533784T1 (de) | Lösliche, einzelkettige proteine des t- zellrezeptors | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| CY1119650T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| CY1110877T1 (el) | Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση | |
| HRP20000714B1 (en) | NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF | |
| CY1110579T1 (el) | Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου | |
| ATE469176T1 (de) | Modifizierter anti-tnf antikörper | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| ATE187494T1 (de) | Multivalente einkettige antikörper | |
| CY1108799T1 (el) | Αντισωμα αντι- ccr5 | |
| ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
| WO1997046589A3 (en) | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods | |
| CY1105563T1 (el) | Συνθεσεις ανοσοποιησης και μεθοδοι χρησης | |
| NO20060189L (no) | Antistoffer mot interleukin-22 og anvendelse derav | |
| CY1106876T1 (el) | Συσκευασια και μεθοδος ανιχνευσεως της πρωτεϊνης esm-1 | |
| CY1115295T1 (el) | Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w | |
| DE69115104D1 (de) | Composition comprising at least two different antibodies or fragments thereof. | |
| WO2002076406A3 (en) | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them | |
| CY1106200T1 (el) | Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους | |
| EA202190599A1 (ru) | Анти-tigit антитела |